A Phase 4 interventional study of dapagliflozin and saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 9 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment, is one of 12 that started in 2021, is one of 77 in phase 4, and was the 137th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 128th largest by enrollment of the 280 interventional ones that give a count, is one of 3 that started in 2021, is one of 28 in phase 4, and was the 310th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients.
During the study, an AstraZeneca representative/delegate will have regular contacts with the study site, including visits to site for the site monitoring and source data verification activities. Electronic Case Report Forms (eCRF) will be used for data collection and query handling. The investigator will sign the completed electronic Case Report Forms. A copy of the completed electronic Case Report Forms will be archived at the study site. Authorized representatives of AstraZeneca or delegate, a regulatory authority, or an Ethics Committee may perform audits or inspections at the center's. Number and percentages of Incidence of adverse events will be presented, stratified by age/gender/baseline medications. Annualised event rate shall also be presented in addition to the incidence rate during the study. Mean change in HbA1C from baseline to 6 months for patients will be analysed using paired t test / Wilcoxon signed-rank test at 5% level of significance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in the study subjects should fulfil the following criteria:
Exclusion criteria:
Patients with any of the following CV/Vascular Diseases within 3 months prior to signing the consent at enrolment, as assessed by the investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
Drug: dapagliflozin and saxagliptin
Drug pages: Dapagliflozin · Saxagliptin
Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
Also known as: QTERN Tablet
Adverse Events (AEs) Including Serious Adverse Events (SAEs), AEs Leading to Discontinuation (DAE), and Adverse Events of Special Interest
Adverse events (AEs) including serious adverse events (SAEs), AEs leading to discontinuation (DAE), and adverse events of special interest (volume depletion, renal events, major hypoglycemic events, fractures, urinary/genital tract infections diabetic ketoacidosis, amputations and hospitalization for heart failure)
Time frame: Baseline to End of Study (Week 26)
Clinically Important or Significant Abnormalities in Safety Laboratory Values
Clinical laboratory results were presented separately for haematology, clinical chemistry, and urinalysis variables. The number of participants with clinically important (haematology and clinical chemistry) or clinically significant (urinalysis) abnormalities in safety laboratory values are presented.
Time frame: Enrolment (Week -1) to End of Study (Week 26)
Clinically Important Abnormalities in ECG Values
The number of participants with clinically important abnormalities in ECG values are presented.
Time frame: Time Frame: Baseline to End of Study (Week 26)
Clinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure)
The number of participants with clinically important abnormalities in vital signs (pulse and blood pressure).
Time frame: Enrolment (Week -1) to End of Study (Week 26)
Clinically Significant Abnormalities in Physical Examinations
The number of participants with clinically significant abnormalities in physical examinations.
Time frame: Enrolment (Week -1) to End of Study (Week 26)
Glycated Haemoglobin (HbA1c) Change at Week 24 Compared to Baseline
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring HbA1c change at week 24 compared to baseline.
Time frame: Baseline to Week 24
Weight Change at Week 24 Compared to Baseline
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring weight change at week 24 compared to baseline.
Time frame: Baseline to Week 24
Systolic Blood Pressure Change at Week 24 Compared to Baseline
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring systolic blood pressure change at week 24 compared to baseline.
Time frame: Baseline to Week 24
Fasting Plasma Glucose Change at Week 24 Compared to Baseline
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring fasting plasma glucose change at week 24 compared to baseline.
Time frame: Baseline to Week 24
| Milestone | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Started | 196 |
| Completed | 173 |
| Not completed | 23 |
| Withdrew: Discontinuation of the study | 14 |
| Withdrew: High plasma glucose-fasting and hba1c; investigator decision to withdraw participant | 1 |
| Withdrew: Withdrawal of informed consent | 8 |
Adverse events (AEs) including serious adverse events (SAEs), AEs leading to discontinuation (DAE), and adverse events of special interest (volume depletion, renal events, major hypoglycemic events, fractures, urinary/genital tract infections diabetic ketoacidosis, amputations and hospitalization for heart failure)
| events | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| AEs | 40 |
| SAEs | 0 |
| DAEs | 0 |
| Adverse events of special interest | 4 |
Clinical laboratory results were presented separately for haematology, clinical chemistry, and urinalysis variables. The number of participants with clinically important (haematology and clinical chemistry) or clinically significant (urinalysis) abnormalities in safety laboratory values are presented.
| Participants | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Clinically Important or Significant Abnormalities in Safety Laboratory Values | 0 |
The number of participants with clinically important abnormalities in ECG values are presented.
| Participants | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Clinically Important Abnormalities in ECG Values | 0 |
The number of participants with clinically important abnormalities in vital signs (pulse and blood pressure).
| Participants | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Clinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure) | 0 |
The number of participants with clinically significant abnormalities in physical examinations.
| Participants | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Clinically Significant Abnormalities in Physical Examinations | 0 |
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring HbA1c change at week 24 compared to baseline.
| percentage of glycated haemoglobin | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Baseline (Visit 2) | 8.6 ± 0.77 |
| Week 24 | 7.4 ± 0.98 |
| Change from Baseline | -1.2 ± 1.09 |
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring weight change at week 24 compared to baseline.
| kilograms | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Baseline (Visit 2) | 74.2 ± 12.59 |
| Week 24 | 72.2 ± 11.51 |
| Change from Baseline | -2.1 ± 3.98 |
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring systolic blood pressure change at week 24 compared to baseline.
| mmHg | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Baseline (Visit 2) | 125.7 ± 9.27 |
| Week 24 | 124.5 ± 10.33 |
| Change from Baseline | -0.2 ± 12.90 |
The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring fasting plasma glucose change at week 24 compared to baseline.
| mg/dL | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Baseline (Visit 2) | 161.8 ± 52.30 |
| Week 24 | 136.7 ± 41.98 |
| Change from Baseline | -24.4 ± 62.89 |
Collected over Week 0 to End of Study (26 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg | 0/196 (0%) | 0/196 (0%) | 22/196 (11.2%) |
| Event | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg |
|---|---|
| Urinary tract infectionInfections and infestations | 5/196 |
| PyrexiaGeneral disorders | 5/196 |
| NasopharyngitisInfections and infestations | 3/196 |
| BalanoposthitisReproductive system and breast disorders | 3/196 |
| NauseaGastrointestinal disorders | 2/196 |
| VomitingGastrointestinal disorders | 2/196 |
| HypersensitivityImmune system disorders | 1/196 |
| Balanitis candidaInfections and infestations | 1/196 |
| PharyngitisInfections and infestations | 1/196 |
| TrichomoniasisInfections and infestations | 1/196 |
Enrolled population
| Age, Continuous(Years) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 52.2 ± 10.27 |
| Sex: Female, Male(Participants) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Female | 76 |
| Male | 120 |
| Race (NIH/OMB)(Participants) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 196 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Height(centimeters) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 163 ± 8.62 |
| Weight(kilograms) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 74.2 ± 12.59 |
| Waist circumference(centimeters) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 97.5 ± 12.76 |
| Body mass index(kg/m^2) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 28.0 ± 4.35 |
| Glycated haemoglobin(percentage of glycated haemoglobin) | Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall |
|---|---|
| Mean | 8.6 ± 0.77 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.'
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2021 to primary completion in Mar 2023, 23 months.
Results were first posted in Nov 2024, 1 year 7 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 23 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Saxagliptin